Introduction {#s1}
============

Pituitary adenomas (PAs) are a common type of intracranial tumor ([@B1]) that accounts for about 10% of intracranial tumors ([@B2]). Clinical manifestations include abnormalities of hormone secretion, pituitary apoplexy, compressing syndromes of tumor that surrounds the pituitary gland, and other anterior pituitary dysfunctions. PAs are divided into functional PAs (FPAs) and nonfunctional PAs (NFPAs) according to their hormone-secreting functions ([@B3]). FPAs display hormone hypersecretion. Because an FPA has its secondary symptoms and signs of excessive secretion of tumor hormones, it is easily diagnosed and treated at an earlier stage. NFPAs do not have any hormone hypersecretion and are more difficult to diagnosis ([@B4]). An NFPA usually has a larger volume at the time of diagnosis, and is often characterized by hypophysis dysfunction, visual field defect, and headache ([@B5]). Although a PA is commonly a benign tumor ([@B6]), secondary symptoms are caused by a large number of hormones produced by FPA and compression of surrounding tissues---causing vision loss, headaches, and so on by NFPA ([@B7]). Therefore, it is necessary to in-depth understand its molecular mechanisms of PAs and to discover novel biomarkers and therapeutic targets for effective treatment of PAs.

Protein ubiquitination is an important post-translational modification (PTM), which plays important roles in maintenance of the balance between protein synthesis and degradation, and in cell signaling, and associates with multiples diseases, including cancers ([@B8], [@B9]). For example, Luo et al. ([@B10]) found that TRAF6 regulates melanoma invasion and metastasis through ubiquitination of Basigin. Ubiquitin is a highly conserved small protein that consists of 76 amino acids, and is a heat-stable protein. In structure, ubiquitin is a polypeptide of 8.5 kDa ([@B9], [@B11], [@B12]). The full length of the ubiquitin molecule contains seven lysine sites (K6, K11, K27, K29, K33, K48, and K63), a methionine site at the N-terminus, and one glycine site at the C-terminus ([@B13], [@B14]). Ubiquitin can be covalently bound to the target protein under catalysis of a series of enzymes. This process is called ubiquitination. Ubiquitination is a process that modulates the PTMs of multiple cells and modifies protein function, stability, and localization ([@B15]--[@B19]). The ubiquitination process involves the synergy of three enzymes: ubiquitin-activating enzyme E1, ubiquitin-coupled enzyme E2, and ubiquitin ligase E3 ([@B20]--[@B22]). First, E1 utilizes the energy provided by ATP to form a high-energy thioester bond between the carboxyl group on the lysine C-terminal Lys residue and the thiol group on its own cysteine residue to activate the ubiquitin molecule. The activated ubiquitin is re-bound to the Cys residue of E2 through the thioester bond. Finally, the activated ubiquitin is either directly linked to the protein substrate via E2, or the ubiquitin is transferred to the ubiquitin to form an amino isopeptide bond between the carboxyl terminal of ubiquitin and the amino group of the Lys residue of the target protein under the action of E3 ([@B9], [@B11]). In this series of enzymatic cascades, E3 plays the most-important role in the specific recognition of target proteins and the regulation of ubiquitination system activity ([@B20], [@B23]), because E3 ligase recognizes substrates through specific protein-protein interactions ([@B21]). E1, E2, and E3 can form several different ubiquitination substrates. Some substrate proteins are only monoubiquitinated, and some have multiple lysine residues. Under appropriate conditions, multiple sites are monoubiquitinated, and some proteins form polyubiquitin chains at a single lysine site.

NFPAs are more common than FPAs in the population of PA patients. However, it is difficult for NFPA patients to obtain an early accurate diagnosis. The treatment of PA patients is generally surgery, radiotherapy, and chemotherapy; however, it is often difficult to achieve a complete cure. It is necessary to investigate new molecular mechanisms of pituitary tumorigenesis and biomarkers for treatment of PAs. Protein ubiquitination is one of PTMs that contribute to the generation of proteoforms. It is well-known that an important function of protein ubiquitination is in the degradation of proteins to maintain the balance of synthesis and degradation of proteins in human body. Furthermore, studies found that the ubiquitin proteasome system changes in pituitary adenomas ([@B24]), and that ubiquitination is involved in pituitary tumorigenesis ([@B25]). Our previous study also identified ubiquitin-proteasome, and that its proteasome subunit alpha type 2 was nitrated in pituitary adenomas, which affected the function of the proteasome that is a multicatalytic proteinase complex in the cytoplasmic and nuclear regions and is involved in an intracellular, ATP/ubiquitin-dependent, nonlysosomal proteolytic pathway ([@B26]). In addition, in our previous series of studies on PA comparative proteomics, an interesting phenomenon is that the number of down-regulated proteins is much more than the number of up-regulated proteins in PAs ([@B27]--[@B30]), the mRNA expression of ubiquitin-conjugating enzymes E2 and E3 was significantly increased in NFPAs ([@B28]), the mRNA expression of ubiquitin specific protease 34 was significantly decreased in PAs ([@B29]), ubiquitin carboxyl-terminal hydrolase isozyme L1 was identified in NFPAs ([@B27]), and the protein ubiquitination pathway was changed in NFPAs ([@B30]). Therefore, it is hypothesized that ubiquitination plays important roles in this interesting phenomenon to discover the key protein ubquitinations for in-depth insights into molecular mechanisms of NFPAs, and to discover reliable biomarkers and effective therapeutic targets. It is important to investigate protein ubiquitinations in human NFPAs.

Anti-ubiquitin antibody-based label-free quantitative proteomics is an effective method to globally detect, identify, and quantify protein ubiquination in a given condition, such as tumors vs. controls ([@B31]--[@B43]). Briefly, the total proteins extracted from tumor and control tissues were digested with trypsin, respectively. The ubiquitinated tryptic peptides in the tryptic peptide mixture were isolated and enriched with an anti-ubiquitin antibody specific to a K-ε-GG group. Isolated ubiquitinated peptides were analyzed with liquid chromatography-tandem mass spectrometry (LC-MS/MS). The MS/MS data were used to search protein database to identify proteins and determine ubiquitinated sites, and the level of protein ubiquitination was determined with MaxQuant algorithms. MaxQuant is the leading qualitative and quantitative algorithm for label-free quantitative proteomics.

Trypsin digestion, anti-ubiquitin antibody-based enrichment, and label-free quantitative proteomics are addressed here. The ubiquitin molecule is made up of 76 amino acids, and the C-terminal glycine is conjugated via its carboxy group to the amino group of a lysine side-chain or to the N-terminus. Trypsin digestion of ubiquitinated proteins cleaves off all but the two C-terminal glycine residues of ubiquitin from the modified protein. These two C-terminal glycine (GG) residues remain linked to the ε-amino group of the modified lysine residue in the tryptic peptide derived from digestion of the substrate protein. The presence of the GG on the side chain of that lysine prevents cleavage by trypsin at that site, to result in an internal modified lysine residue in a formerly ubiquitinated peptide. The K-ε-GG group is recognized and enriched with an antibody specific to K-ε-GG ([@B37]). For the ubiquitinated K (Ub-K) residue at the C-terminus, N-terminus, or the middle in a peptide, it mainly results from steric bulk hindrance, which does not affect the MS identification ([@B42]). The distinct mass shift (114.04 Da) caused by the GG remnant enables identification and precise localization of ubiquitylation sites based on peptide fragments ([@B41]). The identified ubiquitinated peptides were quantified with MaxQuant algorithms ([@B43]).

This study used anti-ubiquitin antibody-based label-free quantitative proteomics to identify ubiquitinated proteins and sites, and to quantify the level of ubiquitination. Pathway network analysis was used to investigate any molecular network alteration that protein ubiquitination is involved in. Selected ubiquitinated proteins were further analyzed to reveal the roles of ubiquitinated proteins in PAs. These findings will help to elucidate the molecular mechanisms, and discover biomarkers and therapeutic targets for PAs.

Materials and Methods {#s2}
=====================

Tissue Samples
--------------

Eight PA tissues were obtained from the Department of Neurosurgery of Xiangya Hospital, China, as approved by the Xiangya Hospital Medical Ethics Committee of Central South University. Post-mortem control pituitary tissues were obtained from the Memphis Regional Medical Center (*n* = 5), as approved by the University of Tennessee Health Science Center Internal Review Board. Written informed consent was obtained from each patient or the family of each control pituitary subject (post-mortem tissues) after full explanation of the purpose and nature of all experimental procedures. The detailed information of PA and control pituitary tissue samples are collected in [Table 1](#T1){ref-type="table"}. Quantitative ubiquitination proteomics was performed between the four mixed NFPA samples and the four mixed control samples. Western blot experiments were performed between the six mixed NFPA samples and the three mixed control samples.

###### 

Clinical characteristic of NFPA and control tissue samples.

  **Group**   **Sex**   **Age**   **Clinical information**                                                                                                     **Immunohistochemistry**                                     **Experiments**
  ----------- --------- --------- ---------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------ --------------------------
  Control     Female    40        White, Multiple toxic compounds. Blood: HepB (+), HepC (+), HIV(--).                                                         DNT                                                          Proteomics; Western blot
              Male      45        White, Drowning. Blood alcohol = 3.1 g/L; no other drugs detected. Blood: HepB (+), HepC (+), HIV (--).                      DNT                                                          Western blot
              Male      36        White, Multiple toxic materials. Blood alcohol = 0.5 g/L. Blood: HepB (+), HepC (--), HIV (--).                              DNT                                                          Proteomics; Western blot
              Female    34        Black, Gunshot wound to chest. Blood alcohol = 0.3 g/L; no drugs. Blood: HepB (+), HepC (--), HIV (--).                      DNT                                                          Proteomics
              Female              White, 15 h gunshot wound to head. No drugs or alcohol. Blood: HepB (--), HepC (--), HIV (--).                               DNT                                                          Proteomics
  NFPA        Female    43        NFPA in sellar region. Sellar floor bone thinning, enriched blood supply in tumor, and tumor size: 4 × 3 × 3 cm^3^           ACTH (--), hGH (--), PRL (--), FSH (+), LH (--), TSH (--)    Proteomics
              Male      53        NFPA in sellar region. Sellar floor bone thinning, and tumor size: 3 × 3 × 2.5 cm^3^                                         ACTH (--), hGH (--), PRL (--), FSH (--), LH (--), TSH (--)   Proteomics
              Female    43        NFPA in sellar region. Adhesion of surrounding tissues, and tumor size: 4.5 × 4 × 6 cm^3^                                    ACTH (--), hGH (--), PRL (--), FSH (+), LH (--), TSH (--)    Proteomics; Western blot
              Male      58        NFPA in sellar region. Sellar floor bone destruction, enriched blood supply in tumor, and tumor size: 4.5 × 3 × 3 cm^3^      ACTH (--), hGH (--), PRL (--), FSH (--), LH (--), TSH (--)   Proteomics; Western blot
              Male      40        NFPA in sellar region. Recurrent tumor, old blooding in tumor, and tumor size 2 × 2 × 1.8 cm^3^.                             ACTH(--), hGH(--), PRL(--), FSH(+), LH(--), TSH(--)          Western blot
              Male      59        NFPA in sellar region. Sellar floor bone thinning, and enriched blood supply in tumor, and tumor size 2.1 × 1.8 × 2 cm^3^.   ACTH(--), hGH(--), PRL(--), FSH(+), LH(--), TSH(--)          Western blot
              Male      49        NFPA in sellar region. Sellar floor bone thinning, old blooding in tumor, and tumor size 2 × 4 × 3 cm^3^.                    ACTH(--), hGH(--), PRL(--), FSH(--), LH(--), TSH(--)         Western blot
              Female    53        NFPA in sellar region. Sellar floor bone thinning, enriched blood supply, and tumor size 3 × 3.5 × 2.5 cm^3^.                ACTH(--), hGH(--), PRL(--), FSH(--), LH(--), TSH(--)         Western blot

*DNT, do not test*.

Cleavage and Quantification of Proteins
---------------------------------------

A volume (1 ml) of urea pyrolysis solution \[20 mM 2-hydroxyethyl (HEPES), 9 M urea, 2.5 mM sodium pyrophosphate, 1 mM sodium orthovanadate, and 1 mM β-glycerophosphate, pH 8.0\] was added to each tissue sample (100 mg) for an ice-bath ultrasonic treatment (100 W, 10 s, interval 10 s, 10 times). The solution was centrifuged (18,000 × g, 30 min, 4°C). The supernatant was the protein extraction, and its protein content was determined with a Bradford Protein Quantification Kit (YEASEN, Cat\# 20202ES76).

Enzymatic Hydrolysis of Proteins
--------------------------------

Four NFPA protein samples (1.5 mg/each sample) were equally mixed as tumor protein sample (6 mg), and four control protein samples (1.5 mg/each sample) were equally mixed as control protein sample (6 mg). Each mixed sample (tumor; control) was equally divided into three parts (2 mg/part) for proteomics experiment. A volume of 1 M dithiothreitol (DTT) was added to each sample part (tumor: *n* = 3; control: *n* = 3) to produce a final concentration of 10 mM; the mixture was incubated (37°C for 2.5 h), and cooled to room temperature. A volume of 1 M iodoacetamide was added to the mixture to achieve a final concentration of 50 mM, and the mixture was incubated in the dark for 30 min. Five volumes of water were added to dilute the urea concentration to 1.5 M. Trypsin (2 μg/μL) was added at 1:50 (v:v) and the mixture was digested (37°C for 18 h). The tryptic peptide mixture was desalted and lyophilized with an SPE C18 column (Waters WAT051910).

Enrichment of Ubiquitinated Peptides
------------------------------------

Each lyophilized tryptic peptide sample (tumor; control) was reconstituted in 1.4 mL of pre-cooled immunoaffinity purification (IAP) buffer. The pretreated anti-K-ε-GG antibody beads \[PTMScan ubiquitin remnant motif (K-ε-GG) kit, Cell Signal Technology\] were added. The mixture was incubated (1.5 h at 4°C) and centrifuged (2,000 × g, 30 s, 4°C). The supernatant was discarded ([@B44]). The pretreated anti-K-ε-GG antibody beads with peptides were washed three times with 1 mL of pre-cooled IAP buffer, and washed three times with 1 mL of pre-chilled water. After washing the anti-K-ε-GG antibody beads with peptides, 40 μL of 0.15% trifluoroacetate (TFA) was added. The mixture was incubated at room temperature for 10 min and centrifuged (30 s at 2,000 × g). The above incubation with 0.15% TFA and centrifugation steps (2,000 × g, 30 s) was performed three times. The supernatant that contained ubiquitinated peptides was desalted with C18 STAGE Tips ([@B45]).

LC-MS/MS Analysis of Enriched Ubiquitinated Peptides
----------------------------------------------------

The enriched ubiquitinated peptides from PA and control tissues were analyzed with LC-MS/MS. Peptides of each sample were separated with a high performance liquid chromatography (HPLC) system EASY-nLC1000 at nanoliter flow rate. The solution A was 0.1% formic acid and 2% acetonitrile aqueous solution. The solution B was 0.1% formic acid and 84% acetonitrile aqueous solution. The chromatographic column was equilibrated with 100% solution A. The enriched ubiquitinated peptide sample was loaded with an autosampler onto a sample-spindle Thermo Scientific EASY column (2 cm^\*^100 μm 5 μm-C18), and peptides were separated with an analytical column of 75 μm × 250 mm 3 μm-C18 at a flow rate of 250 nL/min. The HPLC liquid-phase gradients were as follows: solution B linear gradient from 0 to 55% during 0--220 min, solution B linear gradient from 55 to 100% during 220--228 min, and solution B maintained at 100% during 228--240 min. The enriched peptide products were separated with capillary HPLC according to the HPLC liquid-phase gradients within 240 min, and analyzed with a Q-Exactive mass spectrometer (Thermo Finnigan). The mass spectrometry (MS) detection was in the positive-ion mode. The scan range of the precursor ion was *m/z* 350--1800. The most-intense 20 ions in each MS spectrum were selected for higher-energy collisional dissociation (HCD) fragmentation for MS/MS analysis. The MS resolution was 70,000 at *m/z* 200, and the resolution of MS/MS was 17,500 at *m/z* 200. The enriched ubiquitinated peptide products from PAs or controls were analyzed three times with LC-MS/MS.

Label-Free Analysis With MaxQuant
---------------------------------

Six LC-MS/MS original files (tumor: *n* = 3; Control: *n* = 3) were imported into MaxQuant software (version 1.3.0.5) for database review, protein identification, ubiquitination-site determination, and quantification of ubiquitination level. The protein database was uniprot_human_154578_20160815.fasta (list of 154,578 entries, downloaded on 15 August 2016). The main search parameters were: main search ppm was 6, missed cleavage was 4, MS/MS tolerance ppm was 20, de-isotopic was TRUE, enzyme was trypsin, database was uniprot_human_154578_20160815.fasta, fixed modification was carbamidomethyl (C), variable modification was oxidation (M), acetyl (protein N-term), and GlyGly (K), decoy database pattern was reverse, iBAQ was TRUE, match between analyses was 2 min, peptide false discovery rate (FDR) was 0.01, and protein FDR was 0.01. Thus, the protein was characterized, ubiquitination site was determined with amino acid sequence analysis, and its ubiquitination level was quantified with MaxQuant algorithms.

Statistical and Bioinformatics Analysis
---------------------------------------

The checksum files obtained by MaxQuant were analyzed with Perseus software (version 1.3.0.4). The DAVID database was used to perform KEGG signaling pathway-enrichment analysis of the ubiquitinated proteins. Gene ontology (GO) was used to annotate proteome with R software, and these ubiquitinated proteins were classified with GO annotation based on three categories: cellular components (CC), biological processes (BP), and molecular functions (MF). Motif-X software (<http://motif-x.med.harvard.edu/motif-x.html>) was used to analyze the model of ubiquitinated peptide sequences in specific positions of ubiquityl-31-mers (15 amino acid upstream and 15 amino acid downstream at the ubiquitination site) in all protein sequences. The International Protein Index (IPI) human proteome was used as the background database; setting parameters were width = 15, occurrences = 20, significance = 0.005; other parameters were set to default values.

Western Blot Analysis of 14-3-3 Zeta/Delta Protein
--------------------------------------------------

Six NFPA protein samples were equally mixed as the tumor protein sample, and three control protein samples were equally mixed as the control protein sample ([Table 1](#T1){ref-type="table"}); the equal-load amount (tumor: 22 μg; control: 22 μg) of mixed samples were used for Western blot experiment. Based on the enriched signaling pathways, which include the PI3K-AKT signaling pathway and the Hippo signaling pathway, protein 14-3-3 zeta/delta was the key molecule, and was ubiquitinated in theses pathways; therefore, protein 14-3-3 zeta/delta was selected for Western blot (WB) analysis, and detailed experimental steps for protein extraction was described previously ([@B46]). The anti-protein 14-3-3 zeta/delta antibody (Cusabio, China) was diluted with Tris-buffered saline tween (TBST) (v1: v2 = 1:1000). The secondary antibody (Signalway Antibody, U.S.A.) was diluted with TBST (v1: v2 = 1:5000). The detailed experimental steps for WB were described previously ([@B47]--[@B49]). Briefly, proteins from PA and control samples were separated with 10% SDS-PAGE gel, transferred to a polyvinylidene fluoride (PVDF) membrane, incubated with anti-protein 14-3-3 zeta/delta antibody, incubated with secondary antibody, and visualized.

Results {#s3}
=======

Protein Ubiquitination in Control Pituitaries and Pituitary Adenomas
--------------------------------------------------------------------

Antibody enrichment-based label-free quantitative proteomics identified 158 ubiquitinated sites and 142 ubiquitinated peptides from 108 proteins in PAs and control pituitaries ([Table 2](#T2){ref-type="table"}). A representative MS/MS spectrum was from ubiquitinated peptides ^7^TLTGK^\*^TITLEVEPSDTIENVK^27^ (\[M + 2H\]^2+^, *m/z* = 1202.14; K^\*^ = ubiquitinated lysine residue) of epididymis luminal protein 112 (B2RDW1) or ubiquitin-40S ribosomal protein S27a (P62979) ([Figure 1A](#F1){ref-type="fig"}), with a high-quality MS/MS spectrum, excellent signal-to-noise (S/N) ratio, and extensive product-ion b-ion and y-ion series (b~2~, b~3~, b~4~-H~2~O, b~5~, b~6~, b~7~, b~8~, b~9~, b~10~, b~11~, and b~12~; y~1~, y~2~, y~3~, y~4~, y~5~, y~6~, y~7~, y~8~, y~9~, y~10~, y~11~, y~12~, y~13~, y~14~, y~15~, and y~16~). The ubiquitination site was localized to amino acid residue K${}_{11}^{*}$, and the ubiquitination level was significantly increased in PAs compared to controls ([Table 2](#T2){ref-type="table"}). Another representative MS/MS spectrum was from ubiquitinated peptide ^67^ADALQAGASQFETSAAKLK^\*85^ of uncharacterized protein (L7N2F9) ([Figure 1B](#F1){ref-type="fig"}), which localized the ubiquitination sites at K residue in the peptide C-terminal, with a high-quality MS/MS spectrum, excellent S/N ratio, and extensive product-ion b-ion and y-ion series (b~2~, b~3~, b~4~, b~5~, and b~6~; y~2~, y~3~, y~4~, y~5~, y~6~, y~7~, y~8~, y~9~, y~11~, y~12~, y~13~, y~14~, and y~15~). The ubiquitination site was localized to amino acid residue K${}_{85}^{*}$, and the protein was ubiquitinated in PAs but not in controls ([Table 2](#T2){ref-type="table"}). The third representative MS/MS spectrum was from ubiquitinated peptide ^67^K^\*^VLGAFSDGLAHLDNLK^83^ of hemoglobin subunit beta (P68871) or beta-globin (D9YZU5) ([Figure 1C](#F1){ref-type="fig"}), which localized the ubiquitination site at K residue in the peptide N-terminal, with a high-quality MS/MS spectrum, excellent S/N ratio, and extensive product-ion b-ion and y-ion series (b~2~, b~3~, b~5~, b~6~, b~8~, b~9~, b~10~, b~11~, b~14~, and b~15~; y~1~, y~2~, y~3~, y~4~, y~5~, y~6~, y~7~, y~9~, y~10~, y~11~, y~12~, y~13~, y~14~, y~15~, and y~16~). The ubiquitination site was localized to amino acid residue K${}_{67}^{*}$, and the ubiquitination level was significantly increased in PAs compared to controls ([Table 2](#T2){ref-type="table"}). With the same method, each ubiquitinated peptide and ubiquitination site was identified with MS/MS data, and quantified. Among the 142 ubiquitinated peptides that were identified, 45 ubiquitinated peptides were quantified in PA and control tissues, including 30 statistically significantly differentially ubiquitinated peptides in PAs compared to controls (*p* \< 0.05). A total of 56 ubiquitinated peptides were quantified in PAs, but not in control pituitaries, and six ubiquitinated peptides were quantified in control pituitaries, but not in PAs. A total of 35 ubiquitinated peptides were identified but not quantified in PAs and controls. Moreover, most ubiquitinated peptides were 8--22 amino acids long ([Figure 2A](#F2){ref-type="fig"}). Among 142 ubiquitinated peptides 90.1% (128/142) peptides contained only one ubiquitinated site, 8.5% peptides contained two ubiquitinated sites, 7.8% peptides contained three ubiquitinated sites, and 1.4% peptides contained over three ubiquitinated sites ([Figure 2B](#F2){ref-type="fig"}).

###### 

Ubiquitinated proteins identified in nonfunctional pituitary adenomas relative to controls.

  **Accession No**.   **Gene name**             **Protein name**                                                                                                                     **Modified peptides**             **Peptide length**   **Modified positions**   **Modified probabilities**   **Modified level (N)**   **Modified level (T)**   **Ratio (T/N)**   ***t-*test *p-*value**
  ------------------- ------------------------- ------------------------------------------------------------------------------------------------------------------------------------ --------------------------------- -------------------- ------------------------ ---------------------------- ------------------------ ------------------------ ----------------- ------------------------
  A0A0A6YY96          IREB2                     Iron-responsive element-binding protein 2                                                                                            GFQIAAEK\*QK\*                    10                   483;485                  1; 1                         3.59E+07                 1.62E+08                 4.52              4.55E-06
  P16104              H2AFX                     Histone H2AX                                                                                                                         K\*TSATVGPK                       9                    120                      1                            3.50E+07                 1.43E+09                 40.96             1.39E-05
  P48200              IREB2                     Iron-responsive element-binding protein 2                                                                                            GFQIAAEK\*QK\*                    10                   483;485                  1; 1                         3.46E+07                 1.63E+08                 4.71              3.31E-05
  B2RDW1              RPS30A                    Epididymis luminal protein 112                                                                                                       TLTGK\*TITLEVEPSDTIENVK           21                   11                       1                            1.70E+08                 1.26E+09                 7.40              3.64E-05
                                                                                                                                                                                     TLSDYNIQK\*ESTLHLVLR              18                   63                       1                            3.71E+07                 1.64E+08                 4.43              6.07E-03
                                                                                                                                                                                     LIFAGK\*QLEDGR                    12                   48                       1                            2.91E+09                 7.32E+09                 2.52              6.88E-03
                                                                                                                                                                                     IQDK\*EGIPPDQQR                   13                   33                       1                            2.68E+06                 3.68E+07                 13.74             9.55E-03
                                                                                                                                                                                     TITLEVEPSDTIENVK\*AK              18                   27                       0.956                                                 1.95E+07                                   
                                                                                                                                                                                     MQIFVK\*TLTGK                     11                   6                        0.923                                                                                            
                                                                                                                                                                                     TITLEVEPSDTIENVKAK\*              18                   29                       0.594                                                                                            
                                                                                                                                                                                     VDENGK\*ISR                       9                    113                      1                                                                                                
  P62979              RPS27A                    Ubiquitin-40S ribosomal protein S27a                                                                                                 TLTGK\*TITLEVEPSDTIENVK           21                   11                       1                            1.72E+08                 1.27E+09                 7.37              3.78E-05
                                                                                                                                                                                     TLSDYNIQK\*ESTLHLVLR              18                   63                       1                            3.71E+07                 1.96E+08                 5.27              6.89E-04
  P68871              HBB                       Hemoglobin subunit beta                                                                                                              FFESFGDLSTPDAVMGNPK\*VK\*         21                   60;62                    0.5; 0.5                     1.69E+06                 2.01E+07                 11.87             3.71E-04
                                                                                                                                                                                     GTFATLSELHCDK\*LHVDPENFR          22                   96                       1                            1.89E+07                 9.13E+07                 4.83              1.23E-02
                                                                                                                                                                                     K\*VLGAFSDGLAHLDNLK               17                   67                       1                            2.07E+06                 1.02E+07                 4.92              1.22E-01
  L7N2F9                                        Uncharacterized protein                                                                                                              VNVDK\*VLER                       9                    52                       1                            1.04E+07                 1.23E+08                 11.86             8.99E-04
                                                                                                                                                                                     ADALQAGASQFETSAAK\*LK             19                   83                       0.876                                                 2.01E+07                                   
                                                                                                                                                                                     ADALQAGASQFETSAAKLK\*             19                   85                       0.539                                                 4.61E+07                                   
                                                                                                                                                                                     DQK\*LSELDDR                      10                   59                       1                            6.10E+06                 5.24E+07                 8.60              2.47E-03
  D9YZU5              HBB                       Beta-globin                                                                                                                          FFESFGDLSTPDAVMGNPK\*VK\*         21                   60;62                    0.5; 0.5                     2.48E+06                 2.02E+07                 8.14              1.14E-03
                                                                                                                                                                                     K\*VLGAFSDGLAHLDNLK               17                   67                       1                            1.79E+06                 1.02E+07                 5.69              4.65E-02
  P62979              RPS27A                    Ubiquitin-40S ribosomal protein S27a                                                                                                 IQDK\*EGIPPDQQR                   13                   33                       1                            3.34E+06                 5.10E+07                 15.27             1.16E-03
                                                                                                                                                                                     LIFAGK\*QLEDGR                    12                   48                       1                            2.90E+09                 7.33E+09                 2.53              6.90E-03
  F5H5D3              TUBA1C                    Tubulin alpha-1C chain1                                                                                                              VGINYQPPTVVPGGDLAK\*VQR           21                   370                      1                            2.27E+07                 3.78E+07                 1.67              1.38E-03
                                                                                                                                                                                     DVNAAIATIK\*TK\*                  12                   336;338                  0.679;0.57                                            2.98E+06                                   
  Q9HCC9              ZFYVE28                   Lateral signaling target protein 2                                                                                                   DFCVK\*FPEEIR                     11                   87                       1                            7.36E+06                 2.31E+07                 3.14              1.50E-03
  A0A024R017          HIST1H2AC                 Histone H2A                                                                                                                          NDEELNK\*LLGR                     11                   96                       1                                                     3.45E+06                                   
                                                                                                                                                                                     VTIAQGGVLPNIQAVLLPK\*K\*          20                   119;120                  0.5; 0.5                     6.31E+07                 1.13E+08                 1.80              1.52E-03
  P69905              HBA1                      Hemoglobin subunit alpha                                                                                                             AAWGK\*VGAHAGEYGAEALER            20                   17                       1                                                     7.09E+06                                   
                                                                                                                                                                                     TYFPHFDLSHGSAQVK\*                16                   57                       1                            1.94E+06                 2.06E+08                 106.34            5.10E-03
  P08670              VIM                       Vimentin                                                                                                                             K\*LLEGEESR                       9                    402                      1                            1.70E+06                 5.54E+06                 3.26              5.62E-03
                                                                                                                                                                                     EK\*LQEEMLQR                      10                   188                      1                            1.40E+07                 2.02E+07                 1.44              2.44E-01
                                                                                                                                                                                     QVDQLTNDK\*AR                     11                   168                      1                            1.99E+06                 2.97E+06                 1.49              2.74E-01
                                                                                                                                                                                     K\*LLEGEESR                       9                    393                      1                                                     5.54E+06                                   
  C8C504              HBB                       Beta-globin                                                                                                                          GTFATLSELHCDK\*LHVDPENFR          22                   96                       1                            2.04E+07                 8.43E+07                 4.14              5.79E-03
  Q96T46              HBA2                      Hemoglobin alpha 2                                                                                                                   TYFPHFDLSHGSAQVK\*                16                   33                       1                            1.94E+06                 2.03E+08                 104.44            6.08E-03
  Q9H582              ZNF644                    Zinc finger protein 644                                                                                                              RSFLQQDVNK\*                      10                   11                       1                            9.99E+06                 4.56E+07                 4.56              6.13E-03
  Q9H3H9              TCEAL2                    Transcription elongation factor A protein-like 2                                                                                     QYK\*EAIHDMNFSNEDMIR              18                   154                      1                            3.49E+06                 1.77E+07                 5.07              6.49E-03
  E9PL57              NEDD8-MDP1                Protein NEDD8-MDP1                                                                                                                   TLTGK\*EIEIDIEPTDKVER             19                   11                       1                            3.50E+06                 1.20E+07                 3.43              6.76E-03
  Q59EJ3                                        Heat shock 70kDa protein 1A variant                                                                                                  MVQEAEK\*YK                       9                    592                      0.891                        9.34E+05                 9.36E+06                 10.02             1.11E-02
  D6R956              UCHL1                     Ubiquitin carboxyl-terminal hydrolase                                                                                                CFEK\*NEAIQAAHDAVAQEGQCR          22                   135                      1                                                     5.86E+06                                   
                                                                                                                                                                                     MQLK\*PMEINPEMLNK                 15                   4                        1                            2.77E+06                 8.80E+06                 3.17              1.61E-02
  P14735              IDE                       Insulin-degrading enzyme                                                                                                             EVNAVDSEHEK\*NVMNDAWR             19                   192                      1                            2.05E+06                 7.47E+06                 3.65              1.94E-02
  Q6ZUF2                                        cDNA FLJ43763 fis, clone TESTI2048603                                                                                                FFSPPNMSVTHK\*EAHERK              18                   19                       0.977                        1.39E+08                 2.50E+08                 1.80              5.15E-02
  P61088              UBE2N                     Ubiquitin-conjugating enzyme E2 N                                                                                                    ICLDILKDK\*                       9                    94                       0.962                        1.74E+07                 2.27E+07                 1.30              7.06E-02
  D1MGQ2              HBA2                      Alpha-2 globin chain                                                                                                                 AAWGK\*VGAHAGEYGAEALER            20                   17                       1                                                     7.09E+06                                   
                                                                                                                                                                                     TYFPHFDLSHGSAQVK\*                16                   57                       1                            2.22E+06                 1.26E+08                 56.71             1.21E-01
  P02042              HBD                       Hemoglobin subunit delta                                                                                                             GTFSQLSELHCDK\*LHVDPENFR          22                   96                       1                            1.57E+07                 2.01E+07                 1.28              1.43E-01
  D3DQ48              TMEM59                    Transmembrane protein 59, isoform CRA_e                                                                                              TEDHEEAGPLPTK\*VNLAHSEI           21                   316                      1                            3.64E+06                 1.31E+07                 3.61              1.63E-01
  K7EPI4              GFAP                      Glial fibrillary acidic protein                                                                                                      GGK\*STK\*DGENHK\*                12                   10;13;19                 1;1;1                        2.32E+06                 2.06E+07                 8.87              2.34E-01
  A0A024R5H9          PLEKHB1                   Pleckstrin homology domain containing, family B (Evectins) member 1, isoform CRA_a                                                   LHLCAETK\*DDALAWK                 15                   113                      0.999                        6.23E+06                 0.00E+00                 0.00              1.39E-01
  B7WPA5              PLEKHB2                   Pleckstrin homology domain-containing family B member 2                                                                              QNIEDK\*VHMPMDCINIR               17                   46                       1                            1.30E+07                 7.08E+06                 0.54              3.41E-01
  Q3BBV0              NBPF1                     Neuroblastoma breakpoint family member 1                                                                                             VGWALDMDEIEK\*                    12                   950                      1                            8.76E+06                 5.34E+06                 0.61              4.18E-01
  A4UGR9              XIRP2                     Xin actin-binding repeat-containing protein 2                                                                                        WLFETQPMESLYEK\*                  14                   934                      1                            1.82E+07                 2.61E+07                 1.44              5.39E-01
  B7ZMF0              CEP192                    CEP192 protein                                                                                                                       IVSPK\*NSDLK                      10                   556                      0.908                        1.14E+07                 1.96E+07                 1.71              6.03E-01
  A0N071              HBD                       Delta globin                                                                                                                         GTFSQLSELHCDK\*LHVDPENFR          22                   96                       1                            2.08E+07                 2.20E+07                 1.05              8.73E-01
  A0A024QZP6          H2AFY2                    Core histone macro-H2A                                                                                                               IHPELLAK\*K\*                     9                    116;117                  0.705; 0.585                                                                                     
  A0A024R466          ITM2C                     Integral membrane protein 2C, isoform CRA_a                                                                                          ISFQPAVAGIK\*GDK                  14                   14                       0.855                                                 1.33E+07                                   
  A0A024R6B3          TMEM63C                   Transmembrane protein 63C, isoform CRA_a                                                                                             DIEDPELIIK\*HFHEAYPGSVVTR         23                   239                      1                                                     3.89E+06                                   
  A0A024R7G8          RAD23A                    RAD23 homolog A (*S. cerevisiae*), isoform CRA_a                                                                                     LIYAGK\*ILSDDVPIR                 15                   53                       1                                                     1.24E+07                                   
  A0A024RDB0          UBE1L2                    Ubiquitin-activating enzyme E1-like 2, isoform CRA_a                                                                                 IDAHLNK\*VCPTTETIYNDEFYTK         23                   544                      1                                                     4.66E+06                                   
  A0A087WZE4          SPTA1                     Spectrin alpha chain, erythrocytic 1                                                                                                 VNILTDK\*SYEDPTNIQGK              18                   79                       1                                                     6.34E+06                                   
  A0A0K0KMI2          POU5F1                    POU class 5 homeobox 1 transcript variant OCT4B4                                                                                     K\*LGGQLGR                        8                    1                        1                                                     7.82E+06                                   
  A0A0U1RRH7                                    Histone H2A                                                                                                                          NDEELNK\*LLGK                     11                   96                       0.996                                                                                            
  A0A140VJZ1                                    Testicular tissue protein Li 218                                                                                                     LEK\*IFQNAPTDPTQDFSTQVAK          22                   360                      1                                                                                                
  A0AVT1              UBA6                      Ubiquitin-like modifier-activating enzyme 6                                                                                          IDAHLNK\*VCPTTETIYNDEFYTK         23                   544                      1                                                     4.54E+06                                   
  A4D2P6              GRID2IP                   Delphilin                                                                                                                            GK\*MGTVSK\*SR                    10                   570;576                  1; 1                                                                                             
  A6NNT2              C16orf96                  Uncharacterized protein C16orf96                                                                                                     SALAGK\*ASR                       9                    819                      1                                                                                                
  A6ZKI3              FAM127A                   Protein FAM127A                                                                                                                      K\*ESPLLNDYR                      10                   86                       1                                                     1.64E+07                                   
  A8K6M4                                        cDNA FLJ75725, highly similar to Homo sapiens vesicle transport through interaction with t-SNAREs homolog 1B (yeast) (VTI1B), mRNA   ASSAASSEHFEK\*LHEIFR              18                   13                       1                                                     9.09E+06                                   
  B1A4G6              GH1                       Growth hormone 1 isoform 1                                                                                                           EETQQK\*SNLELLR                   13                   96                       1                            5.87E+06                                                            
  B4DPP6                                        cDNA FLJ54371, highly similar to Serum albumin                                                                                       K\*LVAASQAALGL                    12                   607                      1                                                                                                
                                                                                                                                                                                     K\*QTALVELVK                      10                   558                      1                                                                                                
  B4DR52                                        Histone H2B                                                                                                                          HAVSEGTK\*AVTK                    12                   117                      1                                                     4.70E+07                                   
  B4E1J8                                        cDNA FLJ56285, highly similar to ADP-ribosylation factor-like protein 8B                                                             DLPNALDEK\*QLIEK                  14                   193                      1                                                                                                
  B9EGU6              RC3H1                     Ring finger and CCCH-type zinc finger domains 1                                                                                      KEIMAQLEERK\*                     11                   769                      0.999                                                 7.15E+06                                   
  C9JLQ8              AEBP1                     Adipocyte enhancer-binding protein 1                                                                                                 MPPEKTK\*DK\*                     9                    7;9                      0.985;1                                                                                          
  E7EX29              YWHAZ                     14-3-3 protein zeta/delta                                                                                                            MDKNELVQKAK\*                     11                   11                       0.537                        2.35E+06                                                            
  K7EPF9              APOC1                     Apolipoprotein C-I                                                                                                                   EFGNTLEDK\*AR                     11                   47                       1                                                     7.55E+06                                   
  M1VKI3              SDC4-ROS1_S4;R32          Tyrosine-protein kinase receptor                                                                                                     AGSGSQVPTEPKK\*                   13                   105                      0.554                                                 1.53E+07                                   
  P01241              GH1                       Somatotropin                                                                                                                         EETQQK\*SNLELLR                   13                   96                       1                            4.23E+06                                                            
  P02671              FGA                       Fibrinogen alpha chain                                                                                                               EK\*VTSGSTTTTR                    12                   448                      1                                                     4.06E+06                                   
                                                                                                                                                                                     TVIGPDGHK\*EVTK                   13                   476                      0.86                                                                                             
  P02768              ALB                       Serum albumin                                                                                                                        K\*LVAASQAALGL                    12                   598                      1                                                                                                
                                                                                                                                                                                     K\*QTALVELVK                      10                   549                      1                                                                                                
  P04908              HIST1H2AB                 Histone H2A type 1-B/E                                                                                                               NDEELNK\*LLGR                     11                   96                       1                                                     3.45E+06                                   
  P09960              LTA4H                     Leukotriene A-4 hydrolase                                                                                                            FSYK\*SITTDDWK                    12                   418                      1                                                     4.10E+06                                   
  P19021              PAM                       Peptidyl-glycine alpha-amidating monooxygenase                                                                                       AFGDSEHK\*LETSSGR                 15                   901                      1                                                                                                
  P23396              RPS3                      40S ribosomal protein S3                                                                                                             KPLPDHVSIVEPK\*DEILPTTPISEQK      26                   214                      1                                                     2.84E+07                                   
  P31946              YWHAB                     14-3-3 protein beta/alpha                                                                                                            SELVQKAK\*                        8                    13                       0.672                                                                                            
  P35212              GJA4                      Gap junction alpha-4 protein                                                                                                         ALPAK\*DPQVER                     11                   119                      1                                                     2.26E+06                                   
  P35251              RFC1                      Replication factor C                                                                                                                 KLVSETVK\*                        8                    22                       1                                                                                                
  P45974              USP5                      Ubiquitin carboxyl-terminal hydrolase 5                                                                                              LEK\*IFQNAPTDPTQDFSTQVAK          22                   360                      1                                                     9.83E+06                                   
  P54725              RAD23A                    UV excision repair protein RAD23 homolog A                                                                                           LIYAGK\*ILSDDVPIR                 15                   53                       1                                                     1.39E+07                                   
                                                                                                                                                                                     LIYAGK\*ILNDDTALK                 15                   51                       0.993                                                                                            
  P54727              RAD23B                    UV excision repair protein RAD23 homolog B                                                                                           LIYAGK\*ILNDDTALK                 15                   51                       0.993                                                                                            
  P55072              VCP                       Transitional endoplasmic reticulum ATPase                                                                                            ASGADSK\*GDDLSTAILK               17                   8                        1                                                     7.91E+06                                   
  P60709              ACTB                      Actin, cytoplasmic 1                                                                                                                 DSYVGDEAQSK\*R                    12                   61                       1                                                     2.05E+06                                   
  P60866              RPS20                     40S ribosomal protein S20                                                                                                            DTGK\*TPVEPEVAIHR                 15                   8                        1                                                     9.48E+06                                   
  P61981              YWHAG                     14-3-3 protein gamma                                                                                                                 EQLVQK\*AR                        8                    10                       1                                                                                                
  P62979              RPS27A                    Ubiquitin-40S ribosomal protein S27a                                                                                                 TITLEVEPSDTIENVK\*AK              18                   27                       0.956                                                 1.72E+07                                   
                                                                                                                                                                                     MQIFVK\*TLTGK                     11                   6                        0.923                                                                                            
                                                                                                                                                                                     TITLEVEPSDTIENVKAK\*              18                   29                       0.594                                                                                            
                                                                                                                                                                                     VDENGK\*ISR                       9                    113                      1                                                                                                
  P83916              CBX1                      Chromobox protein homolog 1                                                                                                          KEESEK\*PR                        8                    109                      1                                                                                                
  Q0VDD8              DNAH14                    Dynein heavy chain 14, axonemal                                                                                                      SLLSNVSQWDTFK\*                   13                   2919                     1                                                                                                
  Q13753              LAMC2                     Laminin subunit gamma-2                                                                                                              ITSTFHQDVDGWK\*                   13                   219                      1                                                     1.99E+07                                   
  Q15149              PLEC                      Plectin                                                                                                                              SELELTLGK\*LEQVR                  14                   1210                     1                                                     2.72E+06                                   
  Q4LE39              ARID4B                    AT-rich interactive domain-containing protein 4B                                                                                     K\*ENIK\*PSLGSK\*                 11                   462;466;472              1;1;1                                                 2.05E+07                                   
  Q59EQ3                                        Nudix-type motif 6 isoform a variant                                                                                                 LDAAAFQK\*GLQGK\*                 13                   84;89                    1;1                                                   5.22E+06                                   
  Q5I0G2              PRL                       Growth hormone A1                                                                                                                    AVEIEEQTK\*R                      10                   153                      1                                                     5.21E+06                                   
  Q5JWF2              GNAS                      Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas                                                                  IDVIK\*QADYVPSDQDLLR              18                   829                      1                                                                                                
  Q5VXU3              CHIC1                     Cysteine-rich hydrophobic domain-containing protein 1                                                                                SIQK\*LIEWENNR                    12                   176                      1                                                                                                
  Q92625              ANKS1A                    Ankyrin repeat and SAM domain-containing protein 1A                                                                                  GK\*EQELLEAAR                     11                   3                        1                                                     8.07E+06                                   
  Q93045              STMN2                     Stathmin-2                                                                                                                           DLSLEEIQKK\*                      10                   87                       0.569                                                 2.05E+06                                   
                                                                                                                                                                                     DLSLEEIQK\*K                      10                   86                       0.5                                                                                              
  Q93100              PHKB                      Phosphorylase b kinase regulatory subunit beta                                                                                       AYLQLGINEK\*                      10                   546                      1                            2.91E+07                                                            
  Q96AP7              ESAM                      Endothelial cell-selective adhesion molecule                                                                                         ALEEPANDIK\*EDAIAPR               17                   286                      1                                                                                                
  Q96EI5              TCEAL4                    Transcription elongation factor A protein-like 4                                                                                     EYK\*EAIHDMNFSNEDMIR              18                   142                      1                                                     8.59E+06                                   
  Q96N64              PWWP2A                    PWWP domain-containing protein 2A                                                                                                    TGLEK\*MRSGK\*                    10                   496;501                  1; 1                         1.06E+07                                                            
  Q9BT67              NDFIP1                    NEDD4 family-interacting protein 1                                                                                                   TK\*AEATIPLVPGR                   13                   83                       1                                                                                                
  Q9BUL8              PDCD10                    Programmed cell death protein 10                                                                                                     QILSK\*IPDEINDR                   13                   116                      1                                                     2.54E+07                                   
  Q9BWQ8              FAIM2                     Protein lifeguard 2                                                                                                                  APGTEGQQQVHGEK\*K                 15                   25                       0.822                                                 2.50E+06                                   
  Q9H3Z4              DNAJC5                    DnaJ homolog subfamily C member 5                                                                                                    FK\*EINNAHAILTDATK                16                   58                       1                                                     4.81E+06                                   
  Q9H598              SLC32A1                   Vesicular inhibitory amino acid transporter                                                                                          DQVGGGGEFGGHDK\*PK                16                   113                      0.832                                                 9.03E+06                                   
  Q9NQX7              ITM2C                     Integral membrane protein 2C                                                                                                         ISFQPAVAGIK\*GDK                  14                   14                       0.855                                                 1.33E+07                                   
  Q9NV96              TMEM30A                   Cell cycle control protein 50A                                                                                                       DEVDGGPPCAPGGTAK\*TR              18                   24                       1                                                     3.72E+06                                   
  Q9NX12                                        cDNA FLJ20496 fis, clone KAT08729                                                                                                    SGEEALIIPPDAVAVDCK\*DPDDVVPVGQR   29                   39                       1                                                     6.69E+06                                   
                                                                                                                                                                                     VTFNSALAQK\*EAK                   13                   13                       0.733                                                                                            
  Q9P0M6              H2AFY2                    Core histone macro-H2A.2                                                                                                             IHPELLAK\*K\*                     9                    116;117                  0.705; 0.585                                                                                     
  Q9P1W3              TMEM63C                   Calcium permeable stress-gated cation channel 1                                                                                      DIEDPELIIK\*HFHEAYPGSVVTR         23                   239                      1                                                     5.57E+06                                   
  Q9UBB4              ATXN10                    Ataxin-10                                                                                                                            ITSDEPLTK\*DDIPVFLR               17                   262                      1                                                     1.14E+07                                   
  Q9UEU0              VTI1B                     Vesicle transport through interaction with t-SNAREs homolog 1B                                                                       ASSAASSEHFEK\*LHEIFR              18                   13                       1                                                     9.35E+06                                   
  Q9UF11              PLEKHB1                   Pleckstrin homology domain-containing family B member 1                                                                              LHLCAETK\*DDALAWK                 15                   113                      0.999                        6.23E+06                                                            
  Q9UKJ5              CHIC2                     Cysteine-rich hydrophobic domain-containing protein 2                                                                                SIEK\*LLEWENNR                    12                   117                      1                                                     4.92E+06                                   
  Q9UQB3              CTNND2                    Catenin delta-2                                                                                                                      SPSIDSIQK\*DPR                    12                   540                      1                                                     3.06E+06                                   
  Q9Y287              ITM2B                     Integral membrane protein 2B                                                                                                         SGEEALIIPPDAVAVDCK\*DPDDVVPVGQR   29                   39                       1                                                     6.69E+06                                   
                                                                                                                                                                                     VTFNSALAQK\*EAK                   13                   13                       0.733                                                                                            
  S4R435              RPS10-NUDT3               Protein RPS10-NUDT3                                                                                                                  SAVPPGADKK\*                      10                   139                      0.574                                                 5.99E+07                                   
                                                                                                                                                                                     SAVPPGADK\*K                      10                   138                      0.846                                                 6.91E+07                                   
  U6FSN9              Mprip-Ntrk1 fusion gene   Tyrosine-protein kinase receptor                                                                                                     GWLTK\*QYEDGQWK                   13                   396                      1                                                                                                

*Ratio (T/N), Ration of tumors (B) to controls(A). K^\*^, Ubiquitinated lysine residue*.

![MS/MS spectrum of the tryptic peptide. **(A)** The tryptic peptide TLTGK\*TITLEVEPSDTIENVK from epididymis luminal protein 112 (B2RDW1) or ubiquitin-40S ribosomal protein S27a (P62979). **(B)** The tryptic peptide ADALQAGASQFETSAAKLK\* from uncharacterized protein (L7N2F9). **(C)** The tryptic peptide K\*VLGAFSDGLAHLDNLK from hemoglobin subunit beta (P68871) or beta-globin (D9YZU5). The observed b- and y-ions were labeled in each MS/MS spectrum. K\* = ubiquitinated lysine residue.](fendo-10-00328-g0001){#F1}

![The ubiquitination profile in normal pituitaries and pituitary tumors. **(A)** Peptide length distribution of all ubiquitinated peptides. **(B)** Distribution of ubiquitinated peptides based on number of ubiquitination sites.](fendo-10-00328-g0002){#F2}

Signaling Pathways Involved in Ubiquitinated Proteins
-----------------------------------------------------

Eight statistically significant KEGG signaling pathways (*p* \< 0.05) were identified with DAVID KEGG pathway-enrichment analysis from 108 ubiquitinated proteins, including PI3K-AKT signaling pathway, Hippo signaling pathway, ribosome, nucleotide excision repair, alcoholism, systemic lupus erythematosus, African trypanosomiasis, and malaria. Among them, PI3K-AKT signaling pathway ([Figure 3](#F3){ref-type="fig"}) is activated by many types of cellular stimulation and toxic damage, and regulates essential cellular functions such as transcription, translation, proliferation, survival, and growth. Hippo signaling pathway ([Figure 4](#F4){ref-type="fig"}) is an evolutionarily conserved signaling pathway that controls the size of organs from flies to humans. For human and mouse, Hippo signaling pathway consists of MST1 and MST2 kinases, their cofactors Salvador, LATS1, and LATS2. In response to high cell density, activated LATS1/2 phosphorylates the transcriptional coactivators YAP and TAZ to promote their cytoplasmic localization, leads to apoptosis, and limits organ-size overgrowth. When the Hippo signaling pathway is inactivated at low cell densities, YAP/TAZ translocate into the nucleus to bind to the transcriptional factor enhancer (TEAD/TEF) family to promote cell growth and proliferation. YAP/TAZ also interact with other transcriptional factors or signaling molecules to allow Hippo pathway-mediated processes interact with other key signaling cascade processes, such as TGF-β and Wnt signaling pathways. Because the function of ribosomes is to translate the genetic code (nucleotide sequence) on the mRNA into the amino acid sequence on the polypeptide chain, the ribosome is closely related to protein synthesis. Ribosome signaling pathway ([Figure 5](#F5){ref-type="fig"}) was enriched, and indicated that certain ubiquitinated proteins are closely related to this signaling pathway to thus affect protein synthesis. Nucleotide Excision repair (NER) ([Figure 6](#F6){ref-type="fig"}) is a mechanism to recognize and repair large amounts of DNA damage caused by compounds, environmental carcinogens, and ultraviolet radiation. Protein ubiquitination might be involved in the nucleotide excision repair process to affect protein synthesis and the corresponding biological functions in PAs. Therefore, protein ubiquitination participated in multiple signaling pathway systems and biological processes in human PAs.

![The PI3K-AKT signaling pathway which was achieved by DAVID pathway analysis. The ubiquitinated proteins are shown by red stars.](fendo-10-00328-g0003){#F3}

![The Hippo signaling pathway which was achieved by DAVID pathway analysis. The ubiquitinated subunits are shown by red stars.](fendo-10-00328-g0004){#F4}

![The ribosome signaling pathway which was achieved by DAVID pathway analysis. The ubiquitinated subunits are shown by red stars.](fendo-10-00328-g0005){#F5}

![The nucleotide excision repair which was achieved by DAVID pathway analysis. The ubiquitinated subunits are shown by red stars.](fendo-10-00328-g0006){#F6}

Functional Characteristics of Ubiquitinated Proteins
----------------------------------------------------

In order to further understand the biological function of the ubiquitinated proteins in the development of PAs, GO enrichment analysis of identified ubiquitinated proteins revealed multiple CCs, BPs, and MFs. For CC analysis ([Table 3](#T3){ref-type="table"}), 33 ubiquitinated proteins were assigned to different CCs. A large number of ubiquitinated proteins were located on ribosome and vesicle. It is well-known that ribosomes are complexes composed of rRNA and proteins, and are important sites for protein synthesis. In addition, vesicles and ribosomal subunits also play an important role in protein synthesis. Ubiquitinated proteins can be degraded by the proteasome pathway ([@B8]). When the protein on ribosome or vesicle is usually ubiquitinated, the protein might degrade and affect the synthesis and secretion of other proteins, affect the normal physiological function of the body, and lead to PAs. For BP analysis ([Table 4](#T4){ref-type="table"}), most ubiquitinated proteins were associated with some important biological processes such as cellular responses to certain substances, self-regulation of cells, DNA repair, etc. Abnormal DNA repair was involved in the occurrence and development of tumors ([@B50]). When the proteins involved in DNA repair were ubiquitinated, abnormal DNA repair might occur and lead to PAs. In PA patients, the primary treatment was surgery; however, prolactinomas were usually treated with dopamine agonists ([@B51], [@B52]). The ubiquitinated proteins were associated with drug transport, which might make it difficult for drugs in PA patients to get to the target and thus allow development of tumors. For MF analysis ([Table 5](#T5){ref-type="table"}), 31 ubiquitinated proteins were significantly enriched in different MFs. The molecular functions of enriched ubiquitinated proteins were mainly combined with other substances, such as oxygen, organic acids, cofactors, etc. An important tumor marker was the infinite proliferation of tumor cells and angiogenesis ([@B53]). The proliferation of cells and the production of new blood vessels were inseparable from oxygen and nutrients. Ubiquitinated proteins could bind to oxygen, which might affect the transport of oxygen and nutrients, to thus affect the occurrence and development of PAs.

###### 

Statistically significant GO cellular components (CC) derived from ubiquitinated proteins in human pituitary adenomas.

  **ID**       **Cellular components**                            **GeneRatio**   **BgRatio**   ***P*-value**   ***P*.adjust**   ***Q*-value**   **GeneID**                 **Count**
  ------------ -------------------------------------------------- --------------- ------------- --------------- ---------------- --------------- -------------------------- -----------
  GO:0022627   Cytosolic small ribosomal subunit                  4/33            45/19659      9.34E-07        1.33E-04         8.26E-05        RPS3/RPS20/HBA1/HBA2       4
  GO:0015935   Small ribosomal subunit                            4/33            73/19659      6.60E-06        4.68E-04         2.92E-04        RPS3/RPS20/HBA1/HBA2       4
  GO:0022626   Cytosolic ribosome                                 4/33            115/19659     3.99E-05        1.89E-03         1.18E-03        RPS3/RPS20/HBA1/HBA2       4
  GO:0044445   Cytosolic part                                     5/33            250/19659     5.67E-05        2.01E-03         1.25E-03        IDE/RPS3/RPS20/HBA1/HBA2   5
  GO:0072562   Blood microparticle                                4/33            147/19659     1.04E-04        2.95E-03         1.83E-03        FGA/ALB/HBA1/HBA2          4
  GO:0031838   Haptoglobin-hemoglobin complex                     2/33            11/19659      1.49E-04        3.17E-03         1.97E-03        HBA1/HBA2                  2
  GO:0005833   Hemoglobin complex                                 2/33            12/19659      1.78E-04        3.17E-03         1.97E-03        HBA1/HBA2                  2
  GO:0060198   Clathrin-sculpted vesicle                          2/33            12/19659      1.78E-04        3.17E-03         1.97E-03        DNAJC5/SLC32A1             2
  GO:0044391   Ribosomal subunit                                  4/33            191/19659     2.83E-04        4.47E-03         2.78E-03        RPS3/RPS20/HBA1/HBA2       4
  GO:0071682   Endocytic vesicle lumen                            2/33            19/19659      4.59E-04        6.52E-03         4.06E-03        HBA1/HBA2                  2
  GO:0005840   Ribosome                                           4/33            276/19659     1.13E-03        1.46E-02         9.07E-03        RPS3/RPS20/HBA1/HBA2       4
  GO:0060205   Cytoplasmic vesicle lumen                          4/33            338/19659     2.37E-03        2.62E-02         1.63E-02        FGA/ALB/HBA1/HBA2          4
  GO:0031983   Vesicle lumen                                      4/33            339/19659     2.40E-03        2.62E-02         1.63E-02        FGA/ALB/HBA1/HBA2          4
  GO:0098563   Intrinsic component of synaptic vesicle membrane   2/33            46/19659      2.70E-03        2.74E-02         1.71E-02        DNAJC5/SLC32A1             2
  GO:0035577   Azurophil granule membrane                         2/33            58/19659      4.26E-03        4.03E-02         2.51E-02        DNAJC5/TMEM30A             2
  GO:0030658   Transport vesicle membrane                         3/33            204/19659     4.78E-03        4.24E-02         2.64E-02        DNAJC5/SLC32A1/TMEM30A     3
  GO:0031093   Platelet alpha granule lumen                       2/33            67/19659      5.64E-03        4.71E-02         2.94E-02        FGA/ALB                    2
  GO:0031300   Intrinsic component of organelle membrane          3/33            226/19659     6.34E-03        4.98E-02         3.10E-02        DNAJC5/SLC32A1/ITM2B       3
  GO:0005844   Polysome                                           2/33            73/19659      6.67E-03        4.98E-02         3.10E-02        VIM/RPS3                   2

*GeneRatio = The ratio of the number of genes enriched by the CC to the total number of genes enriched. BgRatio = The ratio of the number of genes contained in the CC to the number of genes in the BP database*.

###### 

Statistically significant GO biological processes (BP) derived from ubiquitinated proteins in human pituitary adenomas.

  **ID**       **Biological process**                                                  **GeneRatio**   **BgRatio**   ***P-*value**   ***P*.adjust**   ***Q*-value**   **GeneID**                  **Count**
  ------------ ----------------------------------------------------------------------- --------------- ------------- --------------- ---------------- --------------- --------------------------- -----------
  GO:0097237   Cellular response to toxic substance                                    5/30            235/18493     3.49E-05        1.66E-02         1.27E-02        ALB/RPS3/HBA1/HBA2/PDCD10   5
  GO:0042542   Response to hydrogen peroxide                                           4/30            141/18493     7.61E-05        1.66E-02         1.27E-02        RPS3/HBA1/HBA2/PDCD10       4
  GO:0045739   Positive regulation of DNA repair                                       3/30            61/18493      1.30E-04        1.66E-02         1.27E-02        H2AFX/RPS3/UBE2N            3
  GO:0042983   Amyloid precursor protein biosynthetic process                          2/30            11/18493      1.39E-04        1.66E-02         1.27E-02        ITM2C/ITM2B                 2
  GO:0042984   Regulation of amyloid precursor protein biosynthetic process            2/30            11/18493      1.39E-04        1.66E-02         1.27E-02        ITM2C/ITM2B                 2
  GO:0046677   Response to antibiotic                                                  5/30            323/18493     1.57E-04        1.66E-02         1.27E-02        RPS3/HBA1/PRL/HBA2/PDCD10   5
  GO:0010561   Negative regulation of glycoprotein biosynthetic process                2/30            12/18493      1.66E-04        1.66E-02         1.27E-02        ITM2C/ITM2B                 2
  GO:0031581   Hemidesmosome assembly                                                  2/30            12/18493      1.66E-04        1.66E-02         1.27E-02        LAMC2/PLEC                  2
  GO:0015671   Oxygen transport                                                        2/30            15/18493      2.64E-04        2.11E-02         1.62E-02        HBA1/HBA2                   2
  GO:1903019   Negative regulation of glycoprotein metabolic process                   2/30            15/18493      2.64E-04        2.11E-02         1.62E-02        ITM2C/ITM2B                 2
  GO:0015893   Drug transport                                                          4/30            217/18493     3.98E-04        2.56E-02         1.96E-02        HBA1/HBA2/SLC32A1/TMEM30A   4
  GO:0015669   Gas transport                                                           2/30            19/18493      4.28E-04        2.56E-02         1.96E-02        HBA1/HBA2                   2
  GO:2001022   Positive regulation of response to DNA damage stimulus                  3/30            92/18493      4.39E-04        2.56E-02         1.96E-02        H2AFX/RPS3/UBE2N            3
  GO:0000302   Response to reactive oxygen species                                     4/30            224/18493     4.48E-04        2.56E-02         1.96E-02        RPS3/HBA1/HBA2/PDCD10       4
  GO:0098869   Cellular oxidant detoxification                                         3/30            101/18493     5.77E-04        3.08E-02         2.36E-02        ALB/HBA1/HBA2               3
  GO:1990748   Cellular detoxification                                                 3/30            105/18493     6.46E-04        3.23E-02         2.47E-02        ALB/HBA1/HBA2               3
  GO:0006282   Regulation of DNA repair                                                3/30            115/18493     8.41E-04        3.96E-02         3.03E-02        H2AFX/RPS3/UBE2N            3
  GO:0031112   Positive regulation of microtubule polymerization or depolymerization   2/30            29/18493      1.01E-03        4.30E-02         3.30E-02        RPS3/STMN2                  2
  GO:0098754   Detoxification                                                          3/30            123/18493     1.02E-03        4.30E-02         3.30E-02        ALB/HBA1/HBA2               3
  GO:0042744   Hydrogen peroxide catabolic process                                     2/30            32/18493      1.22E-03        4.77E-02         3.66E-02        HBA1/HBA2                   2
  GO:0051291   Protein heterooligomerization                                           3/30            132/18493     1.25E-03        4.77E-02         3.66E-02        IDE/HBA1/HBA2               3

*GeneRatio = The ratio of the number of genes enriched by the BP to the total number of genes enriched. BgRatio = The ratio of the number of genes contained in the BP to the number of genes in the BP database*.

###### 

Statistically significant GO molecular functions (MF) derived from ubiquitinated proteins in human pituitary adenomas.

  **ID**       **Molecular functions**      **GeneRatio**   **BgRatio**   ***P*-value**   ***P*.adjust**   ***Q*-value**   **GeneID**               **Count**
  ------------ ---------------------------- --------------- ------------- --------------- ---------------- --------------- ------------------------ -----------
  GO:0019825   Oxygen binding               3/31            36/17632      3.38E-05        4.97E-03         3.48E-03        ALB/HBA1/HBA2            3
  GO:0031720   Haptoglobin binding          2/31            10/17632      1.33E-04        8.10E-03         5.68E-03        HBA1/HBA2                2
  GO:0001540   Amyloid-beta binding         3/31            61/17632      1.65E-04        8.10E-03         5.68E-03        IDE/ITM2C/ITM2B          3
  GO:0005344   Oxygen carrier activity      2/31            14/17632      2.69E-04        9.87E-03         6.93E-03        HBA1/HBA2                2
  GO:0043177   Organic acid binding         4/31            204/17632     4.29E-04        1.12E-02         7.84E-03        ALB/PAM/HBA1/HBA2        4
  GO:0016209   Antioxidant activity         3/31            86/17632      4.56E-04        1.12E-02         7.84E-03        ALB/HBA1/HBA2            3
  GO:0050699   WW domain binding            2/31            31/17632      1.35E-03        2.83E-02         1.99E-02        NDFIP1/TCEAL2            2
  GO:0048037   Cofactor binding             5/31            495/17632     1.59E-03        2.92E-02         2.05E-02        ALB/PAM/RPS3/HBA1/HBA2   5
  GO:0140104   Molecular carrier activity   2/31            43/17632      2.58E-03        4.22E-02         2.96E-02        HBA1/HBA2                2

*GeneRatio = The ratio of the number of genes enriched by the MF to the total number of genes enriched. BgRatio = The ratio of the number of genes contained in the MF to the number of genes in the BP database*.

Characterization of Ubiquitinated Peptides
------------------------------------------

Some studies showed that conservative ubiquitination motifs might not exist in humans ([@B34], [@B40], [@B54]). To elucidate regulation of ubiquitination in human PAs, ubiquitination motif analysis was carried out by examining the sequences from −15 to +15 amino acid residues in the ubiquitination sites of the 142 ubiquitinated peptides with Motif-X software. Five significantly distinguished motifs were identified ([Figures 7A,B](#F7){ref-type="fig"}), including K^\*^-X~(2)~-E, D-X~(4)~-K^\*^, K-X~(4)~-K^\*^, K-X~(3)~-K^\*^, and K^\*^A, which refers to 42, 22, 29, 26, and 23 unique ubiquitinated peptides, respectively (K^\*^ = the ubiquitinated lysine residue; X = any amino acid residue). Those ubiquitinated peptides had different abundances, which together accounted for 99.3% of the identified ubiquitinated peptides ([Figure 7C](#F7){ref-type="fig"}). Although Zhang et al. studied the ubiquitination modification of wheat ([@B55]), the ubiquitination motifs of wheat are completely different from the human ubiquitination motif. This result might reveal differences in ubiquitination motifs among different species. The ubiquitination motifs of human proteins obtained in this study might provide ubiquitin-binding loci for future research. However, one must realize that because this study incorporated a small number of ubiquitinated peptides, the characterized human protein ubiquitination motifs still need to be validated from a large number of ubiquitinated peptide sequences.

![Ubiquitinated protein motifs in human. **(A)** Ubiquitination motifs and the conservation of ubiquitination sites. The central K stands for the ubiquitinated protein. The size of each letter is related to the frequency of amino acid residues occurring at that position. **(B)** Taking the ubiquitinated peptide sequence as a foreground, the sequence window of the ubiquitinated related protein non-ubiquitinated lysine was used as a background control. **(C)** The number of identified ubiquitinated peptides in each motif. K\* = ubiquitinated lysine residue. X = any amino acid residue.](fendo-10-00328-g0007){#F7}

Further Analysis of Ubiquitinated Proteins in Pituitary Adenomas
----------------------------------------------------------------

After comprehensive analysis of ubiquitination data, KEGG pathways, and GO enrichment data, eight statistically significant KEGG signaling pathways (*p* \< 0.05) were identified. Only four of these enriched signaling pathways were associated with tumors, and the protein 14-3-3 zeta/delta was an important molecule in the PI3K-AKT signaling pathway and the Hippo signaling pathway. Also, the peptide from protein 14-3-3 zeta/delta underwent ubiquitination in control pituitary tissues, but not in NFPA tissues ([Table 2](#T2){ref-type="table"}). Therefore, the ubiquitinated protein 14-3-3 zeta/delta was chosen for further analysis with Western immunoaffinity blot. The result showed that protein 14-3-3 zeta/delta was significantly upregulated in NFPAs compared to controls. Quantitative ubiquitinated proteomics showed that the peptide from protein 14-3-3 zeta/delta was ubiquitinated in controls but not in NFPAs ([Figure 8](#F8){ref-type="fig"}; [Table 2](#T2){ref-type="table"}). The decreased ubiquitination level of protein 14-3-3 zeta/delta in NFPAs might inhibit degradation of this protein and change the signaling transduction of this protein in PAs.

![The protein expression level and its ubiquitinated level of protein 14-3-3 zeta/delta in NFPAs compared to controls. **(A)** Western blot analysis of the protein expression level of protein 14-3-3 zeta/delta in NFPAs compared to controls. **(B)** The ubiquitination level of protein 14-3-3 zeta/delta in NFPAs compared to controls. \**p* \< 0.05. \*\**p* \< 0.01. NFPA, nonfunctional pituitary adenomas; Control, control pituitaries.](fendo-10-00328-g0008){#F8}

Discussion {#s4}
==========

The Functions of Protein Ubiquitination
---------------------------------------

Ubiquitination in a protein is under a wide range of functions, and regulates a variety of basic cellular processes, including gene transcription, DNA repair and replication, protein degradation, viral particle sprouting, and intracellular trafficking ([@B56]). Monoubiquitination is involved in the regulation of lysosome targeting, endocytosis, and chromatin remodeling and meiosis. Polyubiquitination involves DNA damage and repair, targets modified proteins to proteasomal degradation, and includes immune signal transduction ([@B17]). Chen et al. suggest that ubiquitination has become a key regulator of the immune system involved in transduction of intracellular signals, control of T cell differentiation, and induction of immune tolerance ([@B57]). The ubiquitination regulatory pattern recognizes receptor signaling, initiates adaptive immune responses, and maturates dendritic cells required to mediate innate immune responses. For T cells, ubiquitination regulates their development, activation, and differentiation to thereby maintain immune tolerance to their own tissues and an effective adaptive immune response to pathogens ([@B20]). The role of ubiquitination in immune regulation was first discovered in studies of antigen presentation and transcription factor nuclear factor NFκB family ([@B58]). The transcription factor nuclear factor NF-κB controls basic functions of many cells, including cell proliferation, immune responses, and apoptosis ([@B59]). Excessive apoptosis can result in anemia, neurodegenerative diseases, and graft rejection. A reduction of apoptosis can lead to autoimmune diseases and cancer. Therefore, moderate apoptosis is of great importance to the body. Ubiquitination of apoptotic proteins is a key component of the apoptosis signaling cascade ([@B60]). The ubiquitination mentioned above has an effect on DNA damage and repair. Improper response of DNA damage might accelerate the aging process, cause genomic instability, and eventually lead to various human diseases, including neurodegenerative diseases and cancer ([@B61]). Ubiquitination plays an important role to regulate the tumor suppressor function of Beclin1 ([@B62]). Thus, ubiquitination might play a crucial part in cancer. Some publications have described that ubiquitination disorders affect the occurrence, development, and metastasis of cancer ([@B22], [@B63], [@B64]).

Ubiquitinated Proteins Regulated Diverse Biological Process
-----------------------------------------------------------

This study found the mainly GO biological processes were related to synthesis and metabolism of proteins, which included glycoprotein, amyloid precursor protein, regulation of proteasomal ubiquitin-dependent protein, etc. This result suggests that ubiquitinated proteins might be involved in the synthesis and metabolism of certain proteins. Our long-term proteomics studies found that the number of down-regulated proteins was much more than up-regulated proteins in different subtypes of NFPAs compared to control pituitaries ([@B28]), mRNA expressions of ubiquitin-conjugating enzymes E2 and E3 were significantly increased in NFPAs ([@B28]), mRNA expression of ubiquitin specific protease 34 was significantly decreased in PAs ([@B29]), proteasome subunit alpha type 2 was nitrated in PAs ([@B26]), and the protein ubiquitination pathway was changed in NFPAs ([@B30]). It is well-known that synthesis and degradation of proteins in humans maintain in a dynamic balance. The increased number of down-regulated proteins in PAs might mean a disrupted balance between synthesis and degradation of proteins compared to control pituitaries. This study clearly found that ubiquitinated proteins in PAs were related to the synthesis and metabolism of proteins. The ubiquitinated proteasome system is one of the main pathways for intracellular protein degradation ([@B8], [@B65], [@B66]). Ubiquitination can achieve protein degradation by ubiquitinating the proteasome. Therefore, the increased number of these downregulated proteins in human NFPAs might undergo ubiquitination to result in more degradation of the proteins relative to normal pituitaries.

The phosphatidylinositol 3-kinase (PI3K)-AKT signaling pathway is activated by many types of cellular and toxic damage and regulates basic cellular functions such as transcription, translation, proliferation, growth, and survival. Binding of growth factors to their receptor tyrosine kinase or G protein-coupled receptor stimulates the Ia and Ib PI3K subtypes, respectively. PI3K catalyzes the production of phosphatidylinositol-3, 4, 5-triphosphate on the cell membrane. PIP3 in turn acts as a second messenger to activate AKT. The activated AKT can control key cellular processes through phosphorylation involved in apoptosis, protein synthesis, metabolism, and cell cycle substrates. The PI3K-AKT signaling pathway is an important signaling pathway in cells, and its main function is to inhibit apoptosis and promote proliferation. In various malignant tumors, the PI3K-AKT signaling pathway is abnormally regulated to promote formation of new blood vessels, proliferation of tumor cells, and inhibition of apoptosis, and is closely related to tumor metastasis and invasion. The HVP90 inhibitor NVPAUY922 and the PI3K-mTOR inhibitor NVP-BEZ235, alone or in combination, have a significant effect on the apoptosis of cholangiocarcinoma cells; and these inhibitors act on the rat model of cholangiocarcinoma to decrease the tumor ([@B67]). These results indirectly indicate that activation of PI3K-AKT signaling pathway contributes to the proliferation of cholangiocarcinoma cells. Study also found that the P110α subunit of PI3K is a regulator of angiogenesis, and the inactivation of P110α leads to non-functional angiogenesis, which in turn prevents tumor growth ([@B68]). In the PI3K-AKT signaling pathway, the key molecules are cytokine, ECM, ITGB, and 14-3-3. Lamnin subunit gamma2 (LAMC2), which is a molecule in ECM, has been reported to be involved in the development and progression of various tumors ([@B69]). Smith et al. ([@B70]) found that LAMC2 was associated with bladder cancer metastasis, and its expression level increased with an increase of human tumor stage. In colorectal cancer, stable overexpressed LAMC2 promotes proliferation, migration, and invasion of cancer cells ([@B71]). The grade of LAMC2 expression was significantly associated with the pattern and depth of invasion of oral squamous cell carcinoma ([@B72]). This study found that LAMC2 was ubiquitinated at position 219. PAs are generally benign tumors, and do not metastasize; however, they do proliferate and invade of tumor cells.

The core components of the Hippo signaling pathway include upstream and downstream regulatory factors, core kinase cassettes, and downstream oncogenes. The core kinase cassette includes Lats1/2, Mst2, SAV1, and Mob. Activation of the Lats1/2 phosphorylation of the transcriptional coactivators YAP and TAZ ultimately leads to apoptosis, limits organ size overgrowth, or promotes cell growth and proliferation ([@B73]). Therefore, the Hippo signaling pathway prevents tissue growth and tumorigenesis ([@B74]). However, the abnormality of this pathway usually leads to the occurrence of tumors ([@B75]). For example, when Lats1 is ubiquitinated, the kinase activity of Lats1 is reduced and subsequently inhibited by Hippo signaling only promotes cell proliferation, but also inhibits cell apoptosis and attenuates tumor suppressor function ([@B76]). NEDD4, an E3 ubiquitin ligase, can directly interact with Lats1 to lead to its ubiquitination and decreased levels of Lats to thereby increase the localization of nuclear YAP, and activate proliferative and anti-apoptotic genes ([@B77]). Lignitto et al. ([@B78]) found that the ubiquitination-proteasome system can degrade Mob to attenuate the Hippo cascade and maintain the growth of glioblastoma cells *in vivo*. So what is the impact of ubiquitination on the Hippo signaling pathway? Toloczko et al. ([@B73]) found that USP9X, a deubiquitinating protease, can enhance LATS kinase to inhibit tumor growth. Therefore, the Hippo signaling pathway is closely related to tumorigenesis, and the ubiquitination and deubiquitination of the core kinase cassette in the Hippo signaling pathway have a great influence on tumor growth. Therefore, ubiquitination and deubiquitination of the core kinase cassette are worthy of further study, and might lead to the development of new treatments for tumors. In addition, some key molecules in the Hippo signaling pathway are 14-3-3 protein and F-actin. The 14-3-3 protein in the Hippo signaling pathway is closely related to tumors.

The Ubiquitination of 14-3-3 Proteins in Pituitary Adenomas
-----------------------------------------------------------

Humans 14-3-3 proteins have many subtypes, including 14-3-3 protein beta/alpha, 14-3-3 protein gamma, 14-3-3 protein theta, etc. 14-3-3 subtypes are considered to play nocogenic roles in a variety of tumors ([@B79]). Raungrut et al. ([@B80]) found that 14-3-3 gamma is involved in the metastasis of lung cancer cells, and found that knockdown of 14-3-3 gamma could inhibit lung cancer metastasis. The 14-3-3 beta protein has been shown to possess carcinogenic potential, and its increased expression has been detected in many types of cancers. Tang et al. ([@B81]) found that 14-3-3 beta promotes migration and invasion of human hepatocellular carcinoma cells by modulating expression of MMP2 and MMP9 through the PI3K/Akt/NF-κB pathway. Also, 14-3-3 τ can promote breast cancer invasion and metastasis by inhibiting RhoGDI ([@B82]). However, few studies are involved in the relationship of 14-3-3 zeta/delta proteins and tumorigenesis. This study found the 14-3-3 zeta/delta protein was ubiquitinated in pituitary control tissues but not in PA tissues. However, Western blot analysis found that 14-3-3 zeta/delta protein was highly expressed in NFPAs compared to control tissues. The ubiquitinated proteasome system is one of the major pathways for intracellular protein degradation ([@B8], [@B65], [@B66]). Ubiquitination can achieve protein degradation by ubiquitination of the proteasome. Thus, it is hypothesized that proteins can be degraded by ubiquitination modification to result in lower protein levels in tumors than control tissues. Therefore, up-regulated expression of 14-3-3 zeta/delta protein in NFPAs might be due to the decreased ubiquitination level, and contribute to pituitary tumorigenesis. These findings might provide a better basis for biomarker discovery and the early treatment of PA patients.

Strengths and Limitations of This Study
---------------------------------------

This study, for the first time, used anti-ubiquitin antibody (specific to K-ε-GG)-based label-free quantitative proteomics to identify protein ubiquitination profiling between NFPAs and control pituitaries. A total of 158 ubiquitinated sites in 108 ubiquitinated proteins was identified and quantified, which is the first ubiquitinome profile in NFPAs compared to controls. Further, pathway network analysis revealed alterations of multiple ubiquitination-involved signaling pathway systems in NFPAs to offer novel insights into molecular mechanisms of NFPAs and to provide a new source to discover new biomarkers for NFPAs. However, one must realize that a ubiquitinome is dynamic, and varies with different conditions and pathophysiological status. PAs are highly heterogeneous among tumor individuals, different subtype of NFPAs, and different subtypes of FPAs. In order to further in-depth insight into functional significance of each ubiquitination in PA pathogenesis, one must significantly expand the number of human tissue samples studied to validate and quantify each ubiquitination among individuals and different PA subtypes; also, biological functions of each ubiquitination should be examined in the cell model and animal model. For this current study, due to the very limited, precious pituitary adenoma and control tissue samples, only very limited amount of proteins were used for trypsin digestion, anti-ubiquitin antibody-based enrichment, and LC-MS/MS analysis. The number of ubiquitinated sites and ubiquitinated proteins might be significantly increased with an increased amount of proteins in future ubiquitinomics analysis among PA individuals and among different PA subtypes, to significantly expand the ubiquitinome database of PAs, which will offer the increased opportunity to in-depth explore biological roles of protein ubiquitination in PAs.

Conclusion {#s5}
==========

Ant-ubiquitin antibody-based label-free quantitative proteomics effectively identified and quantified protein lysine ubiquitination in human PAs compared to controls. This study provides the first protein ubiquitination profiling of human PAs and control pituitaries to understand ubiquitination-mediated multiple cellular functions and biological processes. This study expanded the range of physiological processes regulated by ubiquitination, and serves as a valuable reference for biological functions of protein ubiquitination in human PAs.
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